New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer
Jayant S Vaidya,Max Bulsara,Michael Baum,Frederik Wenz,Samuele Massarut,Steffi Pigorsch,Michael Alvarado,Michael Douek,Christobel Saunders,Henrik Flyger,Wolfgang Eiermann,Chris Brew-Graves,Norman R Williams,Ingrid Potyka,Nicholas Roberts,Marcelle Bernstein,Douglas Brown,Elena Sperk,Siobhan Laws,Marc Sütterlin,Tammy Corica,Steinar Lundgren,Dennis Holmes,Lorenzo Vinante,Fernando Bozza,Montserrat Pazos,Magali Le Blanc-Onfroy,Günther Gruber,Wojciech Polkowski,Konstantin J Dedes,Marcus Niewald,Jens Blohmer,David McReady,Richard Hoefer,Pond Kelemen,Gloria Petralia,Mary Falzon,David Joseph,Jeffrey S Tobias
DOI: https://doi.org/10.1038/s41416-021-01440-8
Abstract:Background: The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses. Methods: In total, 2298 women (≥45 years, invasive ductal carcinoma ≤3.5 cm, cN0-N1) were randomised. We investigated the impact of tumour size, grade, ER, PgR, HER2 and lymph node status on local recurrence-free survival, and of local recurrence on distant relapse and mortality. We analysed the predictive factors for recommending supplemental EBRT after TARGIT-IORT as part of the risk-adapted approach, using regression modelling. Non-breast cancer mortality was compared between TARGIT-IORT plus EBRT vs. EBRT. Results: Local recurrence-free survival was no different between TARGIT-IORT and EBRT, in every tumour subgroup. Unlike in the EBRT arm, local recurrence in the TARGIT-IORT arm was not a predictor of a higher risk of distant relapse or death. Our new predictive tool for recommending supplemental EBRT after TARGIT-IORT is at https://targit.org.uk/addrt . Non-breast cancer mortality was significantly lower in the TARGIT-IORT arm, even when patients received supplemental EBRT, HR 0.38 (95% CI 0.17-0.88) P = 0.0091. Conclusion: TARGIT-IORT is as effective as EBRT in all subgroups. Local recurrence after TARGIT-IORT, unlike after EBRT, has a good prognosis. TARGIT-IORT might have a beneficial abscopal effect. Trial registration: ISRCTN34086741 (21/7/2004), NCT00983684 (24/9/2009).